Trial Profile
A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 06 Apr 2017 Status changed from not yet recruiting to discontinued due to Insufficient recruitment rate.
- 12 May 2016 New trial record